Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Payables (2017 - 2026)

Bioceres Crop Solutions' Payables history spans 10 years, with the latest figure at $66.4 million for Q1 2026.

  • On a quarterly basis, Payables fell 63.34% to $66.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $66.4 million, a 63.34% decrease, with the full-year FY2025 number at $216.1 million, down 29.25% from a year prior.
  • Payables hit $66.4 million in Q1 2026 for Bioceres Crop Solutions, down from $216.1 million in the prior quarter.
  • Over the last five years, Payables for BIOX hit a ceiling of $305.5 million in Q2 2024 and a floor of $66.4 million in Q1 2026.
  • Historically, Payables has averaged $198.9 million across 5 years, with a median of $198.6 million in 2025.
  • Biggest five-year swings in Payables: soared 55.73% in 2023 and later plummeted 63.34% in 2026.
  • Tracing BIOX's Payables over 5 years: stood at $166.0 million in 2022, then surged by 55.73% to $258.4 million in 2023, then rose by 18.2% to $305.5 million in 2024, then dropped by 29.25% to $216.1 million in 2025, then tumbled by 69.28% to $66.4 million in 2026.
  • Business Quant data shows Payables for BIOX at $66.4 million in Q1 2026, $216.1 million in Q2 2025, and $181.1 million in Q1 2025.